Wen‐Zhao Zhong

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research · 2016 · 992 citations

Medicine, Immunology, Oncology +17

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 529 citations

Medicine, Oncology, Pharmacology +10

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu et al. · OncoImmunology · 2017 · 445 citations · Full text

Life Sciences, Immunology, Oncology +17

Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn et al. · New England Journal of Medicine · 2024 · 382 citations

Medicine, Oncology, Medical Oncology +6

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Y.S. Li, Bo Jiang, Jin‐Ji Yang et al. · Annals of Oncology · 2018 · 330 citations · Full text

Medicine, Genetics, Oncology +17